Mode
Text Size
Log in / Sign up

Diabetic Nephropathy

Part of Diabetes

11 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Diabetic Nephropathy

15 trials tracked for Diabetic Nephropathy: 9 in phase 3 or 4 and 4 with published results. The most-cited published study has 133 citations.

15Trials tracked
9Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 4 Phase 3 5 Phase 2 6
  1. Phase 4 Nephropathy In Type 2 Diabetes and Cardio-renal Events Completed · 133 cited
  2. Phase 3 Effect of Sulodexide in Early Diabetic Nephropathy Completed · 115 cited
  3. Phase 3 Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy Completed · 31 cited
  4. Phase 3 Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy Completed · 7 cited
  5. Phase 4 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy Completed
  6. Phase 4 Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM) Completed
Show 9 more trials
  1. Phase 4 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes Completed
  2. Phase 3 ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial Completed
  3. Phase 3 Renoprotection in Early Diabetic Nephropathy in Pima Indians Completed
  4. Phase 2 The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors Completed
  5. Phase 2 Study of LY3016859 in Participants With Diabetic Nephropathy Completed
  6. Phase 2 A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy Completed
  7. Phase 2 Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy Completed
  8. Phase 2 Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients Completed
  9. Phase 2 N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Diabetic Nephropathy: what the trials found

Canagliflozin has demonstrated significant clinical benefits in patients with diabetic nephropathy. It significantly reduced the primary composite endpoint of doubling of serum creatinine, end-stage kidney disease, and renal or cardiovascular death (61.24% vs 43.21%, p<0.0001) 7. Additionally, Canagliflozin was associated with a significant reduction in the composite endpoint of cardiovascular death and hospitalized heart failure (45.44% vs 31.47%, p=0.0001) and a reduction in major adverse cardiac events (MACE) (48.67% vs 38.71%, p=0.0121) 7.

While Canagliflozin showed significant reductions in composite renal and cardiovascular outcomes, specific findings regarding eGFR decline were mixed; one trial reported no statistically significant difference in the change from baseline in eGFR at week 104 (p=0.351) 6. In other trials, standard of care was associated with a reduction in MACE compared to alternative treatments (146 vs 116, p<0.05) 1.

Other interventions investigated include sodium bicarbonate 2, Cyclosporin 3, Lipo-PGE1 4, Sulodexide 5, and Losartan 8. Olmesartan medoxomil showed no significant difference in renal composite outcomes (p=0.79) but did show a statistically significant reduction in cardiovascular composite outcomes (40 vs 53, p=0.039) 9.

Recent results — preliminary, needs further review

  • Nidufexor showed a ratio to baseline in urinary albumin to creatinine ratio (UACR) of 0.85-1.06 and stable eGFR ratios (0.94-0.98) 10.
  • PF-04634817 demonstrated a reduction from baseline in UACR at week 12 (13.27% vs 5.02%) 14.
  • Zemplar (paricalcitol) did not show statistically significant results for UACR reduction (p=0.071) or albumin levels (p=0.855) 15.

For the clinician treating this condition

  • Canagliflozin is supported by evidence for reducing primary composite renal endpoints and improving cardiovascular outcomes, including reduced heart failure hospitalizations and MACE.
  • Olmesartan medoxomil showed significant improvements in cardiovascular composite outcomes despite no significant difference in renal composite outcomes.
  • Standard of care was associated with a statistically significant reduction in major adverse cardiovascular events (MACE) compared to the alternative intervention studied.

AI synthesis of 12 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Diabetes

Related studies from across the Diabetes family.

DEKODE platform protocol aims to improve clinical and process outcomes in diabetic ketoacidosis
Diabetes & Endocrinology Guideline
DEKODE platform protocol aims to improve clinical and process outcomes in diabetic ketoacidosis New Digital System Aims to Improve Diabetic Ketoacidosis Care
This guideline outlines a study protocol for the DEKODE platform, a cloud-based audit-and-feedback system for managing diabetic ketoacidosis…
A new digital audit system aims to standardize care and improve outcomes for patients experiencing diabetic ketoacidosis in hospital setting…
Press needle and plum-blossom needle combination significantly lowers pro-inflammatory cytokines in diabetic peripheral neuropathy
Diabetes & Endocrinology RCT
Press needle and plum-blossom needle combination significantly lowers pro-inflammatory cytokines in diabetic peripheral neuropathy Acupuncture Techniques May Improve Nerve Function in Diabetic Patients
This randomized controlled trial of 225 patients with diabetic peripheral neuropathy found that press needle embedding combined with plum-bl…
A new trial suggests that specific acupuncture techniques may lower inflammation and improve nerve conduction in people with diabetic periph…
SGLT2 inhibitors reduce risk of diabetic retinopathy progression (rr 0.77) and macular edema progression (rr 0.75)
Ophthalmology Meta-analysis
SGLT2 inhibitors reduce risk of diabetic retinopathy progression (rr 0.77) and macular edema progression (rr 0.75) SGLT2 inhibitors show promise in slowing diabetic eye disease
This meta-analysis of 1,785,409 patients with established diabetic retinopathy (DR) or diabetic macular edema (DME) found that SGLT2i therap…
A large analysis suggests SGLT2 inhibitors may slow the progression of vision-threatening complications in people with diabetes.
Mass spectrometry identifies 681 differentially expressed proteins in patients with proliferative diabetic retinopathy
Ophthalmology Meta-analysis
Mass spectrometry identifies 681 differentially expressed proteins in patients with proliferative diabetic retinopathy Proteomics Analysis Identifies Key Proteins in Diabetic Retinopathy
This meta-analysis of proteomics data using mass spectrometry identified 681 differentially expressed proteins in patients with proliferativ…
New research identifies specific proteins and biological pathways linked to proliferative diabetic retinopathy to help guide future medical …
Higher Triglyceride-glucose index is associated with increased risk of diabetic peripheral neuropathy
Diabetes & Endocrinology Meta-analysis
Higher Triglyceride-glucose index is associated with increased risk of diabetic peripheral neuropathy High Triglyceride and Glucose Levels Linked to Nerve Damage in Diabetes
This meta-analysis of 32,281 patients with Type 2 Diabetes found that a higher TyG index is associated with an increased risk of diabetic pe…
High levels of fats and sugars in the blood can significantly increase the risk of nerve damage for people with type 2 diabetes.
Moxibustion Combination Therapies Improve Nerve Conduction and Clinical Scores in Diabetic Neuropathy
Diabetes & Endocrinology Meta-analysis
Moxibustion Combination Therapies Improve Nerve Conduction and Clinical Scores in Diabetic Neuropathy Moxibustion combinations may improve nerve function in diabetic neuropathy
A network meta-analysis suggests moxibustion combined with herbal medicine or acupuncture may improve nerve conduction and clinical scores i…
Combining moxibustion with herbal medicine or acupuncture may improve nerve conduction and scores for people with diabetic peripheral neurop…
Ranibizumab port delivery system shows noninferior BCVA gains and low supplemental treatment requirements in diabetic retinopathy
Oncology Meta-analysis
Ranibizumab port delivery system shows noninferior BCVA gains and low supplemental treatment requirements in diabetic retinopathy Ranibizumab port delivery system shows promise for diabetic eye conditions
This meta-analysis evaluates the ranibizumab port delivery system (PDS) for patients with diabetic retinopathy and diabetic macular edema. T…
A new delivery system for ranibizumab shows consistent results for patients with diabetic retinopathy and macular edema.
Invasive spinal cord stimulation provides variable relief across diverse chronic neuropathic pain conditions
Neurology Sys. Review
Invasive spinal cord stimulation provides variable relief across diverse chronic neuropathic pain conditions Different types of spinal cord stimulation help various chronic pains
This narrative review synthesizes evidence on invasive spinal cord stimulation (SCS) for various neurological and pain conditions. The autho…
Newer forms of spinal cord stimulation offer promising relief for complex nerve pain and failed back surgeries, but results vary by conditio…
Pharmacist-led medication therapy management improves adherence and glycemic control in a patient with complex T2DM
Rheumatology Sys. Review
Pharmacist-led medication therapy management improves adherence and glycemic control in a patient with complex T2DM Pharmacist-led care improves blood sugar for woman with long-term diabetes
This case report describes a single patient with type 2 diabetes who received pharmacist-led medication therapy management. The intervention…
A pharmacist-led review helped a woman with a 30-year history of Type 2 Diabetes significantly improve her medication adherence and blood su…
Intravenous alpha-lipoic acid optimizes symptom relief while oral administration supports structural repair in DPN
Neurology Meta-analysis
Intravenous alpha-lipoic acid optimizes symptom relief while oral administration supports structural repair in DPN Different ways to give alpha-lipoic acid help diabetic nerve pain
This Bayesian network meta-analysis evaluates various alpha-lipoic acid (ALA) administration routes for diabetic peripheral neuropathy. Find…
New data shows that intravenous and oral versions of alpha-lipoic acid offer different benefits for managing symptoms and repairing nerves i…
Microvascular alteration is a statistically significant determinant for diabetic peripheral neuropathy prevalence
Neurology Meta-analysis
Microvascular alteration is a statistically significant determinant for diabetic peripheral neuropathy prevalence New data reveals key drivers of nerve damage in diabetes
This meta-analysis of 83,560 patients across 24 countries identified a global diabetic peripheral neuropathy (DPN) prevalence of 57.42% (95%…
Over half of people with diabetes suffer from nerve damage, but new data highlights specific blood vessel changes as a primary driver of the…
Spinal cord stimulation with medical management reduces pain intensity in painful diabetic neuropathy
Anesthesiology & Pain Medicine Meta-analysis
Spinal cord stimulation with medical management reduces pain intensity in painful diabetic neuropathy Spinal Cord Stimulation Shows Promise for Diabetic Neuropathy Pain
This meta-analysis of adults with painful diabetic neuropathy found that spinal cord stimulation combined with conventional medical manageme…
Adding spinal cord stimulation to standard medical care may significantly reduce pain intensity for adults living with painful diabetic neur…